A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of Oral Ozanimod As Induction Therapy For Moderately To Severely Active Crohn's Disease
Principal Investigator(s)
Email for information
Funded by
GENEVA
Research Start Date
Status
Active
The primary objective of this study is to demonstrate the efficacy of ozanimod compared to placebo on the maintenance of clinical remission and endoscopic response in patients with moderately to severely active Crohn's Disease.
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.